Brought to you by 
Maverick Capital leads $39.7mm private financing for XenoPort
08 Jan 2009
Executive Summary
XenoPort, which uses transporter proteins found in the GI tract to improve drug absorption, netted $39.7mm in a registered direct offering of 1.9mm shares at $21.17 each (a slight discount to the market average) to lead investor Maverick Capital as well as Venrock Healthcare Capital Partners and VCHP Co-Investment Holdings. Backers also received five-year warrants to purchase another 283k shares for $25.40 apiece.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com